Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 16, 2026
Renal Function During and After 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Journal: Journal of nuclear medicine technology
Published: February 26, 2026
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.
Journal: The Lancet. Oncology
Published: August 07, 2025
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 07, 2025
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 18, 2025
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.
Journal: The Lancet. Oncology
Published: April 17, 2025
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 06, 2025
Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 10, 2025
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.
Journal: The Lancet. Oncology
Published: July 09, 2024
Peptide receptor radionuclide therapy for ectopic Cushing's syndrome caused by metastatic neuroendocrine neoplasms.
Journal: Endocrine oncology (Bristol, England)
Published: April 16, 2024
Showing 1-11 of 11
Last Updated: 09/26/2026